Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05023551 · ClinicalTrials.gov registry record · Early Phase 1
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
A Early Phase 1 study of Glioblastoma Multiforme and High Grade Glioma, sponsored by Sumitomo Pharma America.
- Active
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
- 9
- Study locations
NCT05023551 is a Early Phase 1 study of Glioblastoma Multiforme and High Grade Glioma that is active but no longer recruiting, run by Sumitomo Pharma America. The registered enrollment target is 39 participants, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (59% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT05023551, a Early Phase 1 study of Glioblastoma Multiforme and High Grade Glioma, is active but no longer recruiting, sponsored by Sumitomo Pharma America.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a study of DSP-0390 in patients with recurrent high grade glioma.
Conditions Studied
Interventions
- DRUG DSP-0390
Study Locations (9)
California
- University of California at San Francisco - San Francisco
Massachusetts
- Dana Farber Cancer Institute - Boston
Missouri
- Washington University School of Medicine - St Louis
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
New York
- Columbia University - New York
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Hokkaido
- Hokkaido University Hospital - Sapporo
Sakyo-ku
- Kyoto University Hospital - Kyoto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2021-09-08 |
| Est. Completion | 2026-10-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05023551
The ClinicalTrials.gov registry entry for NCT05023551 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (59% lower). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which DSP-0390 is the first listed.
NCT05023551 reports 9 study locations spanning 9 distinct geographic areas - top geographies include California, Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT05023551 about?
NCT05023551 is a clinical study titled "Study of DSP-0390 in Patients With Recurrent High-Grade Glioma". This is a study of DSP-0390 in patients with recurrent high grade glioma.
What is the current status of trial NCT05023551?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2021-09-08. Estimated completion is 2026-10-31.
What conditions does trial NCT05023551 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, High Grade Glioma.
What interventions are being tested in trial NCT05023551?
The interventions under investigation include: DSP-0390 (DRUG).
Who is sponsoring clinical trial NCT05023551?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05023551 being conducted?
This trial has 9 study locations across California, Massachusetts, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
RECRUITING · Early Phase 1
-
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
ACTIVE NOT RECRUITING · Early Phase 1
-
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
ACTIVE NOT RECRUITING · Early Phase 1
-
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
ACTIVE NOT RECRUITING · Early Phase 1
-
Study of Pamiparib in Newly Diagnosed and rGBM
ACTIVE NOT RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.